Epidemiology & Biostatistics

The Ed Reznik Lab

Ed Reznik, PhD

Assistant Professor

The Reznik Lab studies metabolic and mitochondrial dysfunction in cancer through analysis of multimodal genetic, metabolomic, and clinical data. We use computational tools to address a basic question: how do tumors adapt their metabolism, the process by which they obtain energy and nutrition from the extracellular environment, to sustain malignancy? Our research draws on data from basic science and clinical practice to understand how metabolic adaptations confer selective advantages to tumors, serve as biomarkers of response and resistance to therapy, and poise tumors for effective targeted intervention.

The lab’s research is equal parts machine learning, data science, and bioinformatics, and is conducted by a multidisciplinary group of quantitative scientists and translationally-minded physicians. We study metabolism in many disease contexts, but also have a unique translational focus on kidney cancer.

Publications Highlights

Tang C, Xie AX, Liu EM, Kuo F, Kim M, DiNatale RG, Golkaram M, Chen YB, Gupta S, Motzer RJ, Russo P, Coleman J, Carlo MI, Voss MH, Kotecha RR, Lee CH, Tansey W, Schultz N, Hakimi AA, Reznik E. Immunometabolic coevolution defines unique microenvironmental niches in ccRCC. Cell Metab. 2023 Aug 8;35(8):1424-1440.e5. doi: 10.1016/j.cmet.2023.06.005. Epub 2023 Jul 5.

Benedetti E, Liu EM, Tang C, Kuo F, Buyukozkan M, Park T, Park J, Correa F, Hakimi AA, Intlekofer AM, Krumsiek J, Reznik E. A multimodal atlas of tumour metabolism reveals the architecture of gene-metabolite covariation. Nat Metab. 2023 Jun;5(6):1029-1044. doi: 10.1038/s42255-023-00817-8. Epub 2023 Jun 19. PMID: 37337120; PMCID: PMC10290959.

Posada Calderon L, Eismann L, Reese SW, Reznik E, Hakimi AA. Advances in Imaging-Based Biomarkers in Renal Cell Carcinoma: A Critical Analysis of the Current Literature. Cancers (Basel). 2023 Jan 5;15(2):354. doi: 10.3390/cancers15020354. PMID: 36672304; PMCID: PMC9856305.

Golkaram M, Kuo F, Gupta S, Carlo MI, Salmans ML, Vijayaraghavan R, Tang C, Makarov V, Rappold P, Blum KA, Zhao C, Mehio R, Zhang S, Godsey J, Pawlowski T, DiNatale RG, Morris LGT, Durack J, Russo P, Kotecha RR, Coleman J, Chen YB, Reuter VE, Motzer RJ, Voss MH, Liu L, Reznik E, Chan TA, Hakimi AA. Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape. Genome Med. 2022 Dec 19;14(1):143. doi: 10.1186/s13073-022-01146-3. PMID: 36536472; PMCID: PMC9762114.

Rappold PM, Vuong L, Leibold J, Chakiryan NH, Curry M, Kuo F, Sabio E, Jiang H, Nixon BG, Liu M, Berglund AE, Silagy AW, Mascareno A, Golkaram M, Marker M, Reising A, Savchenko A, Millholland JM, Chen YB, Russo P, Coleman J, Reznik E, Manley BJ, Ostrovnaya I, Makarov V, DiNatale RG, Blum KA, Ma X, Chowell D, Li MO, Solit DB, Lowe SW, Chan TA, Motzer RJ, Voss MH, Hakimi AA. A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear Cell Renal Cell Carcinoma. Cancer Discov. 2022 Jun 27:candisc.0925.2021. doi: 10.1158/2159-8290.CD-21-0925. Epub ahead of print. PMID: 35758895.

View All Publications

People

Ed Reznik, PhD

Assistant Professor

The Reznik Lab studies metabolic and mitochondrial dysfunction in cancer through analysis of multimodal genetic, metabolomic, and clinical data.
PhD, Boston College